Opioid Use Disorder Market to Grow Rapidly at a CAGR of 4.2% by 2032, Predicts DelveInsight

The opioid use disorder market is expected to grow in the coming years due to factors like an increase in the patient pool and the expected entry of emerging therapies by leading companies such as Braeburn Pharmaceuticals, BioXcel Therapeutics, MediciNova, AstraZeneca, and others.

LAS VEGAS, April 26, 2023 /PRNewswire/ -- DelveInsight's Opioid Use Disorder Market Insights report includes a comprehensive understanding of current treatment practices, opioid use disorder emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Opioid Use Disorder Market Report

• As per DelveInsight analysis, the opioid use disorder market size in the 7MM was approximately USD 1.9 billion in 2022.
• According to the assessment done by DelveInsight, the estimated total prevalent opioid use disorder cases in the 7MM were approximately 3.9 million in 2022. 
• Leading opioid use disorder companies such as Braeburn Pharmaceuticals, BioXcel Therapeutics, MediciNova, AstraZeneca, Cerevel Therapeutics, LLC, Indivior Inc., Aptinyx, and others are developing novel opioid use disorder drugs that can be available in the opioid use disorder market in the coming years.
• The promising opioid use disorder therapies in the pipeline include CAM2038, BXCL501, MN-166, AZD4041, CVL-354, INDV-2000, NYX-783, and others.
• In December 2022, FDA accepted Braeburn's NDA resubmission for BRIXADI (buprenorphine) extended-release subcutaneous injection for moderate to severe opioid use disorder.

Discover which therapies are expected to grab the major opioid use disorder market share @ Opioid Use Disorder Market Report

Opioid Use Disorder Overview

Opioids are substances that interact with opioid receptors in the body and brain to diminish pain perception. They can be natural, semi-synthetic, or synthetic. While the terms opioids and opiates are sometimes used interchangeably, opiate explicitly refers to natural substances derived from the poppy plant, such as heroin or morphine. In contrast, opioids can be natural or synthetically derived.

Opioid use disorder is defined as the prolonged use of opioids that causes clinically substantial distress or impairment. Opioid use disorder is characterized by an overwhelming desire to use opioids, increased opioid tolerance, and withdrawal symptoms when opioids are withdrawn. The most severe form of opioid use disorder includes dependency and addiction.  Opioid use disorder has substantial potential effects, including disability, relapses, and death. The Diagnostic and Statistical Manual of Mental Disorders defines opioid use disorder as a problematic pattern of opioid use that causes issues or distress.

Opioid Use Disorder Epidemiology Segmentation

DelveInsight estimates that there were approximately 3.9 million prevalent cases of opioid use disorder in the 7MM in 2022.

According to estimates based on DelveInsight's analysis, the United States contributed to the largest number of diagnosed prevalent cases of opioid use disorder (~53%) in the 7MM in 2022. Whereas EU4 and the UK accounted for around 36% of the total prevalent cases of opioid use disorder in the 7MM, respectively, in 2022.

The opioid use disorder market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Opioid Use Disorder Prevalent Cases
• Opioid Use Disorder Gender-Specific Cases
• Opioid Use Disorder Age-Specific Cases
• Opioid Use Disorder Severity-Specific Cases

Download the report to understand which factors are driving opioid use disorder epidemiology trends @ Opioid Use Disorder Epidemiological Insights

Opioid Use Disorder Treatment Market 

Although effective therapies are available, only roughly 1 in every 4 patients with OUD receives specialized care. Medication for opioid use disorder (MOUD), considered the "gold standard" of opioid use disorder treatment, is an evidence-based treatment for people suffering from opioid use disorder. Counseling and behavioral therapies may be an important aspect of opioid use disorder treatment in addition to drugs, but they are not successful on their own. Medications are also used to treat cravings, alleviate withdrawal symptoms, and prevent opioid euphoria. These drugs do not "cure" the illness but rather increase safety and minimize withdrawal symptoms, which might lead to relapse or continuing drug use. Methadone, buprenorphine, and naltrexone are three FDA-approved drugs often used for opioid use disorder treatment.

Unlike individuals with substance-use disorders, individuals with other diseases, individuals with substance-use disorders are encouraged to participate in self-help programs such as Alcoholics Anonymous and Narcotics Anonymous. The combination of education, motivational enhancement, and self-help groups, which are incorporated into individual and group counseling approaches in inpatient and outpatient programs, helps patients change how they think about how opioids affect their lives, recognize that change is possible, and work to reduce behaviors that perpetuate illicit drug use while developing new behaviors that reduce drug-related problems.

To know more about opioid use disorder treatment guidelines, visit @ Opioid Use Disorder Management 

Opioid Use Disorder Pipeline Therapies and Key Companies

• CAM2038: Braeburn Pharmaceuticals
• BXCL501: BioXcel Therapeutics
• MN-166: MediciNova
• AZD4041: AstraZeneca
• CVL-354: Cerevel Therapeutics, LLC
• INDV-2000: Indivior Inc.
• NYX-783: Aptinyx

Learn more about the FDA-approved drugs for opioid use disorder @ Drugs for Opioid Use Disorder Treatment 

Opioid Use Disorder Market Dynamics

The opioid use disorder market dynamics are expected to change in the coming years.  After the United States acknowledged and addressed its opioid issue, there has been an increase in awareness and overall financing for opioid use disorder research and development in the opioid use disorder market. Although just a few active compounds have been demonstrated to be beneficial in opioid use disorder treatment, their various and creative formulations have revolutionized the therapeutic landscape by considerably enhancing treatment adherence among patients and reducing relapses. Moreover, the elimination of the DATA 2000 waiver and the cap on how many patients can be treated with buprenorphine by a physician is expected to revolutionize the opioid use disorder market landscape in the US, expanding the use of buprenorphine in the treatment environment even more. Furthermore, the upcoming policy reforms are projected to improve opioid use disorder patients' access to MOUD and their use in the therapy environment.

However, several factors may hamper opioid use disorder market growth in the coming years. Despite being demonstrated to be the greatest opioid use disorder treatment option, the use of MOUD in the treatment context is relatively low in the US, as opioid agonist therapy, which is the most recommended type of opioid use disorder treatment, is often perceived as a person changing from one form of addiction to another. Because of the societal stigma connected with drugs in Japan, therapeutic choices are restricted, and many individuals may be misdiagnosed. In addition, low-cost generics can frequently jeopardize the opioid use disorder market expansion of freshly produced products. Moreover, MOUD is most effective for long-term success when therapy is initiated willingly rather than coerced or mandated. Additionally, MOUD treatment reimbursement is inconsistent across the United States, with policies varying by state. Thus all these factors may cause a dip in the growth of the opioid use disorder market in the future.

Scope of the Opioid Use Disorder Market Report

• Therapeutic Assessment: Opioid Use Disorder current marketed and emerging therapies
• Opioid Use Disorder Market Dynamics: Attribute Analysis of Emerging Opioid Use Disorder Drugs 
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's Views, Analyst's Views, Opioid Use Disorder Market Access and Reimbursement

Discover more about opioid use disorder drugs in development @ Opioid Use Disorder Clinical Trials

Table of Contents 

Related Reports

Opioid Use Disorder Epidemiology Forecast

Opioid Use Disorder Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted opioid use disorder epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Opioid Dependence Market

Opioid Dependence Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key opioid dependence companies, including GW Pharmaceuticals, Opiant Pharmaceuticals, ATAI Life Sciences, C4X Discovery, among others.

Opioid-Related Disorder Pipeline

Opioid-Related Disorder Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key opioid-related disorder companies, including GW Pharmaceuticals, Opiant Pharmaceuticals, Trevi Therapeutics, Aphios, among others.

Opioid Withdrawal Syndrome Pipeline

Opioid Withdrawal Syndrome Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key opioid withdrawal syndrome companies, including Chiesi Farmaceutici S.p.A., BioXcel Therapeutics, Aphios Pharmaceutical, among others.

Opioid-Related Disorder Market

Opioid-Related Disorder Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key opioid-related disorder companies, including GW Pharmaceuticals, Opiant Pharmaceuticals, Trevi Therapeutics, Aphios, among others.

Opioid Withdrawal Syndrome Market

Opioid Withdrawal Syndrome Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key opioid withdrawal syndrome companies, including Chiesi Farmaceutici S.p.A., BioXcel Therapeutics, Aphios Pharmaceutical, among others.

Other Trending Reports

Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market 

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Contact Us

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg